Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review

Telles, João Paulo; Cieslinski, Juliette; Tuon, Felipe Francisco

doi:10.1016/j.bjid.2019.05.006

Cited by 37 publications

(18 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The low efficacy of vancomycin against staphylococcal biofilms could be due to a reduced biofilm penetration, a reduced concentration of free vancomycin being sequestrated by S. aureus on peptidoglycan layers, or a stimulation of biofilm formation by low concentrations of vancomycin (Broussou et al, 2018). Conversely, daptomycin has shown a superior efficacy against bone and joint infections caused by MRSA (Chang et al, 2017;Telles et al, 2019). The consistent synergistic effect observed with Sb-1/daptomycin combination against all tested rifampin-resistant MRSA strains in our study, together with the good biofilm penetration properties (Ozturk et al, 2016) and in vitro activity against stationary-phase bacteria inside the biofilm (Smith et al, 2009), makes daptomycin a promising candidate for combinatorial therapy.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Staphylococcal Bacteriophage Sb-1 as an Adjunctive Agent to Antibiotics Against Rifampin-Resistant Staphylococcus aureus Biofilms

et al. 2020

View full text Add to dashboard Cite

Rifampin plays a crucial role in the treatment of staphylococcal implant-associated infection, as it is the only antibiotic capable of eradicating Staphylococcus aureus biofilms. However, the emergence of rifampin resistance strongly limits its use. Combinatorial therapy of antibiotics and bacteriophages may represent a strategy to overcome the resistance. Here, we evaluated the activity of staphylococcal bacteriophage Sb-1 in combination with different antibiotics against the biofilms of 10 rifampin-resistant S. aureus clinical strains, including MRSA and MSSA. S. aureus biofilms formed on porous glass beads were exposed to antibiotics alone or combined with Sb-1 simultaneously or staggered (first Sb-1 for 24 h followed by antibiotic). Recovered bacteria were detected by measuring growth-related heat production at 37°C (isothermal microcalorimetry) and the biofilm eradication was assessed by sonication of beads and plating of the resulting sonication fluid. Minimum biofilm eradication concentration (MBEC) was defined as the lowest concentration of antibiotic required to kill all adherent bacteria, resulting in absence of growth after plating the sonication fluid. Tested antibiotics presented high MBEC values when administered alone (64 to > 1,024 μg/ml). The simultaneous or staggered combination of Sb-1 with daptomycin showed the highest activity against all MRSA biofilms, whereas the exposure to Sb-1 with vancomycin showed no improved anti-biofilm activity. Staggered administration of Sb-1 and flucloxacillin, cefazolin, or fosfomycin improved the antibiofilm activity in four out of six MSSA, whereas simultaneous exposure exhibited similar or lesser synergy. In conclusion, the combinatorial effect of Sb-1 and antibiotics enabled to eradicate rifampin-resistant S. aureus biofilms in vitro .

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Staphylococcal Bacteriophage Sb-1 as an Adjunctive Agent to Antibiotics Against Rifampin-Resistant Staphylococcus aureus Biofilms

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 10 Vancomycin and teicoplanin are highly effective in treatment of serious MRSA infections; however, the suboptimal response often necessitates the addition of a second or third antimicrobial agent, such as rifampicin and aminoglycosides. 11 , 12 Reasonable empirical antibiotic treatments in limb-threatening infections include a combination of an anti-anaerobic agent like clindamycin and an anti-aerobic antibiotic. 13 Over the past few years, new cephalosporins with improved activity against Staphylococcus aureus have been discovered; however, their antimicrobial activities are insufficient to eradicate MRSA infection, 14 except for the fourth generation parenteral cephalosporin, which has shown good antibacterial activity against MRSA.…”

Section: Introductionmentioning

confidence: 99%

<p>Antimicrobial Susceptibility Testing and Phenotypic Detection of MRSA Isolated from Diabetic Foot Infection</p>

Anwar¹,

Hussein²,

Salih³

2020

IJGM

View full text Add to dashboard Cite

Background: Diabetic foot infection (DFI) is a common and costly complication of diabetes that may be caused by various bacteria with multi-resistant genes. The aim of this study is to evaluate the efficacy of phenotypic methods for identification of methicillinresistant Staphylococcus aureus (MRSA) with genotypic detection of MRSA-related genes. Methods: In this cross-sectional study, swab samples were collected from patients with DFI from hospitals in Sulaimani/Iraq in April-July 2019. All the samples were processed for microbiological assessment and further MRSA phenotypic and genotypic testing. Results: A total of 46 swab samples were collected from diabetic foot ulcers of 29 males and 17 females. Most samples (93.5%) showed positive growth, with higher proportions of monomicrobial (23; 53.5%) than mixed-bacterial infections (20; 46.5%) and S. aureus as the predominant pathogen. Conventional methods of MRSA detection, such as cefoxitin disc diffusion, can predict methicillin resistance in 45.8% of the cases. Real-time/conventional PCR showed that 41.6% of Staphylococcus aureus were positive for the mecA gene, while none of the isolates was positive for PVL. Conclusion: Staphylococcus aureus was the predominant pathogen in DFI. Although cefoxitin and oxacillin disc diffusion methods can help in the prediction of MRSA, realtime PCR is a reliable method for MRSA detection and confirmation.

show abstract

“…Next, we evaluated the effect of the combination of tedizolid-rifampicin on 48-h-old MSSA and MRSA biofilms. The combination daptomycin-rifampicin has been included as a positive control according to previous data supporting the efficacy in biofilm-related infections ( LaPlante and Woodmansee, 2009 ; Hall Snyder et al, 2015 ; Telles et al, 2019 ; Kamble and Pardesi, 2020 ).…”

Section: Resultsmentioning

confidence: 99%

Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm

et al. 2020

View full text Add to dashboard Cite

Staphylococcus aureus infections associated with implanted medical devices are difficult to treat and require long-lasting antibiotic therapies, especially when device removal is not possible or easy such as in the case of joint prostheses. Biofilm formation is a major cause of treatment failure and infection recurrence. This study aimed to test, for the first time, the in vitro combination of tedizolid plus rifampicin on methicillin-sensitive (MSSA ATCC 6538) and methicillin-resistant (MRSA ATCC 43300) S. aureus mature biofilm. Here, we demonstrated that the combination of tedizolid with rifampicin significantly disaggregated pre-formed biofilm of both strains, reduced their metabolic activity and exerted bactericidal activity at clinically meaningful concentrations. Notably, tedizolid was able to completely prevent the emergence of resistance to rifampicin. Moreover these effects were similar to those obtained with daptomycin plus rifampicin, a well-known and widely used combination. Preliminary results on some MRSA clinical isolates confirmed the efficacy of this combination in reducing biofilm biomass and preventing rifampicin resistance onset. Further in vivo studies are needed to confirm the validity of this promising therapeutic option that can be useful against biofilm-associated S. aureus infections.

show abstract

Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review

Cited by 37 publications

References 51 publications

Evaluation of Staphylococcal Bacteriophage Sb-1 as an Adjunctive Agent to Antibiotics Against Rifampin-Resistant Staphylococcus aureus Biofilms

Evaluation of Staphylococcal Bacteriophage Sb-1 as an Adjunctive Agent to Antibiotics Against Rifampin-Resistant Staphylococcus aureus Biofilms

<p>Antimicrobial Susceptibility Testing and Phenotypic Detection of MRSA Isolated from Diabetic Foot Infection</p>

Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm

Contact Info

Product

Resources

About